It is worth noting that in relation to CPVT, AAV-mediated delivery of a CaMKII peptide inhibitor (autocamtide-2-related inhibitory peptide, AIP) has been shown to suppress ventricular arrhythmias induced by either β-adrenergic stimulation or programmed ventricular pacing. This evidence concerns the gene AIP and catecholaminergic polymorphic ventricular tachycardia.